Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 10, 2025-- Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to…
Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts
PBGENE-HBV, the first gene editing therapy designed to treat chronic Hepatitis B by directly targeting HBV cccDNA and integrated HBV DNA, showcased as the final oral presentation in the late-breaking…
Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update
- Late-breaking oral presentation at the Liver Meeting ® 2025 to feature new data from multiple cohorts of the Phase 1 ELIMINATE-B trial of PBGENE-HBV in chronic hepatitis B - Commenced dosing in…
Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025
DURHAM, N.C. --(BUSINESS WIRE)--Oct. 31, 2025-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo…
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025
DURHAM, N.C. --(BUSINESS WIRE)--Oct. 14, 2025-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo…
Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases
- Publication describes how the unique qualities of ARCUS nucleases contribute to precise and efficient gene editing for gene insertion, single base editing, specific small and large deletions, and…
Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial
- Massachusetts General Hospital , Harvard Medical School , actively recruiting chronic hepatitis B patients along with multiple global clinical trial sites - - Phase 1 ELIMINATE-B trial for…
Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society
- Data to highlight latest long-term preclinical efficacy and durability data supporting PBGENE-DMD for the treatment of Duchenne Muscular Dystrophy - - On track to file an IND and/or CTA by the…
Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 12, 2025-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo…
Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status
- Strengthens the Company’s intellectual property portfolio for lead in vivo program PBGENE-HBV with U.S. patent protection into 2042- - Phase 1 ELIMINATE-B trial progressing through clinical…
Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update
- Continued rapid progress with Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV for Hepatitis B; Announced safety and efficacy for Cohort 1 and safety data for Cohort 2 - PBGENE-HBV demonstrated…
Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B
- Proof-of-activity now established for PBGENE-HBV, the first and only clinical modality designed to eliminate covalently closed circular DNA (cccDNA) and inactivate integrated DNA, with the goal of…